Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis.

ABSTRACT:

Background

Both the US FDA and the European Medicines Agency (EMA) have approved aripiprazole for use in adolescents for specific indications. Given the assumed favorable side-effect profile of aripiprazole, its use in children and adolescents has increased for both official and off-label indications (anxiety disorders, eating disorders, personality disorders). However, several cases of children and adolescents with new-onset extrapyramidal symptoms (EPS) after commencing treatment with aripiprazole have been reported, and a more systematic appraisal of this possible risk is lacking.

Objective

We conducted a systematic review and a meta-analysis to assess the evidence for acute EPS (acute dystonia, akathisia, Parkinsonism) associated with the use of aripiprazole in children

SUBMITTER: Bernagie C 

PROVIDER: S-EPMC4996892 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature